Janett Schwarz, Ph.D.

Dr. Schwarz has more than 10 years’ experience in drug discovery. She has worked along the drug discovery value chain in both Germany and the United States. She has deep expertise in the development and optimization of ELISA and cell-based assays, the identification, selection and optimization of drug candidates and the usage of high throughput screening technology (in combination with both NCE and NBE libraries). At IPM Biotech she is responsible for development and validation of immunogenicity (screening/confirmatory/neutralizing) and PK assays using ELISA and ECL-based immunoassays (MSD) under GLP regulations for support of preclinical and clinical studies.

Janett majored in Biochemistry and graduated from Leibniz University Hannover and obtained her Ph.D. at the department of Toxicology / Medical School Hannover. Prior to joining BioAgilytix, Janett has worked for an innovative German start-up as scientist in the pre-clinical development of protein-based cancer drug candidates and for The Scripps Research Institute in San Diego / USA as research fellow in the field of drug discovery and optimization. Additionally, she is an author or co-author of several peer-reviewed publications and scientific abstracts presented at international meetings.